vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $14.9M, roughly 1.3× EVERSPIN TECHNOLOGIES INC.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -64.1%, a 62.1% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs 9.8%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
ENTA vs MRAM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $14.9M |
| Net Profit | $-11.9M | $-296.0K |
| Gross Margin | — | 52.7% |
| Operating Margin | -60.5% | 29.0% |
| Net Margin | -64.1% | -2.0% |
| Revenue YoY | 9.8% | 13.2% |
| Net Profit YoY | 46.4% | — |
| EPS (diluted) | $-0.42 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $18.6M | $14.8M | ||
| Q3 25 | $15.1M | $14.1M | ||
| Q2 25 | $18.3M | $13.2M | ||
| Q1 25 | $14.9M | $13.1M | ||
| Q4 24 | $17.0M | $13.2M | ||
| Q3 24 | $14.6M | $12.1M | ||
| Q2 24 | $18.0M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $-11.9M | $1.2M | ||
| Q3 25 | $-18.7M | $54.0K | ||
| Q2 25 | $-18.3M | $-670.0K | ||
| Q1 25 | $-22.6M | $-1.2M | ||
| Q4 24 | $-22.3M | $1.2M | ||
| Q3 24 | $-28.8M | $2.3M | ||
| Q2 24 | $-22.7M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | — | 50.8% | ||
| Q3 25 | — | 51.3% | ||
| Q2 25 | — | 51.3% | ||
| Q1 25 | — | 51.4% | ||
| Q4 24 | — | 51.3% | ||
| Q3 24 | — | 49.2% | ||
| Q2 24 | — | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | -60.5% | -7.2% | ||
| Q3 25 | -121.6% | -11.0% | ||
| Q2 25 | -103.2% | -14.9% | ||
| Q1 25 | -164.3% | -14.7% | ||
| Q4 24 | -138.8% | -11.8% | ||
| Q3 24 | -204.4% | -17.5% | ||
| Q2 24 | -134.6% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | -64.1% | 8.1% | ||
| Q3 25 | -123.6% | 0.4% | ||
| Q2 25 | -99.7% | -5.1% | ||
| Q1 25 | -151.7% | -8.9% | ||
| Q4 24 | -131.4% | 9.2% | ||
| Q3 24 | -197.3% | 18.8% | ||
| Q2 24 | -126.1% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $-0.42 | $0.05 | ||
| Q3 25 | $-0.88 | $0.00 | ||
| Q2 25 | $-0.85 | $-0.03 | ||
| Q1 25 | $-1.06 | $-0.05 | ||
| Q4 24 | $-1.05 | $0.07 | ||
| Q3 24 | $-1.36 | $0.10 | ||
| Q2 24 | $-1.07 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $70.2M |
| Total Assets | $329.5M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $37.4M | $44.5M | ||
| Q3 25 | $32.3M | $45.3M | ||
| Q2 25 | $44.8M | $45.0M | ||
| Q1 25 | $60.2M | $42.2M | ||
| Q4 24 | $84.3M | $42.1M | ||
| Q3 24 | $37.2M | $39.6M | ||
| Q2 24 | $35.8M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $126.6M | $68.9M | ||
| Q3 25 | $64.7M | $65.8M | ||
| Q2 25 | $79.3M | $64.1M | ||
| Q1 25 | $93.5M | $63.0M | ||
| Q4 24 | $111.8M | $62.6M | ||
| Q3 24 | $128.8M | $59.3M | ||
| Q2 24 | $148.9M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $329.5M | $84.6M | ||
| Q3 25 | $280.7M | $80.3M | ||
| Q2 25 | $301.0M | $78.9M | ||
| Q1 25 | $323.0M | $80.2M | ||
| Q4 24 | $348.6M | $77.8M | ||
| Q3 24 | $376.7M | $72.6M | ||
| Q2 24 | $398.8M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $570.0K |
| Free Cash FlowOCF − Capex | $-11.8M | — |
| FCF MarginFCF / Revenue | -63.6% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $-11.7M | $2.6M | ||
| Q3 25 | $-6.5M | $881.0K | ||
| Q2 25 | $17.5M | $5.0M | ||
| Q1 25 | $-13.5M | $1.4M | ||
| Q4 24 | $-16.8M | $3.8M | ||
| Q3 24 | $-10.4M | $2.8M | ||
| Q2 24 | $-14.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-11.8M | $-975.0K | ||
| Q3 25 | $-7.9M | $543.0K | ||
| Q2 25 | $17.4M | $3.0M | ||
| Q1 25 | $-16.0M | $527.0K | ||
| Q4 24 | $-25.5M | $2.1M | ||
| Q3 24 | $-19.4M | $2.8M | ||
| Q2 24 | $-21.3M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | -63.6% | -6.6% | ||
| Q3 25 | -52.5% | 3.9% | ||
| Q2 25 | 94.7% | 22.9% | ||
| Q1 25 | -107.4% | 4.0% | ||
| Q4 24 | -150.6% | 15.8% | ||
| Q3 24 | -132.5% | 22.9% | ||
| Q2 24 | -118.6% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 24.3% | ||
| Q3 25 | 9.6% | 2.4% | ||
| Q2 25 | 0.8% | 15.1% | ||
| Q1 25 | 17.0% | 6.9% | ||
| Q4 24 | 51.6% | 13.2% | ||
| Q3 24 | 61.3% | 0.5% | ||
| Q2 24 | 36.4% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTA
Segment breakdown not available.
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
